Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension

NCT02480764 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02480764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02480764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
August 27, 2015
Completion date
October 13, 2017
Enrollment
612 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension